LOW DOSE TAMOXIFEN AS TREATMENT OF BENIGN BREAST
PROLIFERATIVE LESIONS
CRISTIAN BĂLĂLĂU1, ȘTEFAN VOICULESCU2*, ION MOTOFEI1, RĂZVAN VALENTIN SCĂUNAȘU2, CAROLINA NEGREI3
1Department of General Surgery, “Carol Davila” University of Medicineand Pharmacy, “St. Pantelimon” Emergency
Universitary Hospital, 340-342, Pantelimon Main Road , Sector 2, Bucharest, Romania
2Department of General Surgery, “Carol Davila” University of Medicineand Pharmacy, Colțea Universitary Hospital, 1,
I.C. Bratianu Boulevard, Sector 3 Bucharest, Romania
3Department of Toxicology, “Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, 6, Traian Vuia
Street, 020956, Bucharest, Romania
*corresponding author: s_voiculescu@yahoo.com
Download Full Article

Abstract:
The presence of oestrogen receptors in breast structures defining benign lesions, enlights the opportunity of using tamoxifen
for this pathology. Tamoxifen is a selective oestrogen receptor modulator (SERM) with tissue-specific activities: it acts as an
anti-oestrogen (inhibiting agent) in the mammary tissue, but as an oestrogen (stimulating agent) on the cholesterol
metabolism, bone density, and cell proliferation in the endometrium and thus may be characterized as a mixed
agonist/antagonist.
Our study started from the observation that adapting doses for less dramatic breast pathology may significantly reduce the
number and incidence of side effects, while remaining effective for the treatment and prevention of recurrent benign breast
diseases and, probably, breast cancer [15, 17].
The results of our study suggest that low doses of tamoxifen may be prescribed for benign breast pathology expecting
excellent results, especially for proliferative lesions (hyperplasia) and adenosis, associated with a very low rate of side effects
incidence.

Top